Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Viridian Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 72 | 84 | +12 |
| Shares | 24.9M | 28.3M | +3.39M (+13.6%) |
| Value | $460.9M | $327.7M | −$133.2M (−28.9%) |
New holders (32)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (20)
Institutions that held Viridian Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Avidity Partners Management LP | 1,040,000 | $19.2M |
| Silverarc Capital Management, LLC | 126,136 | $2.33M |
| ExodusPoint Capital Management, LP | 97,745 | $1.81M |
| Endurant Capital Management LP | 83,217 | $1.54M |
| Goldman Sachs Group Inc | 66,598 | $1.23M |
| Jane Street Group, LLC | 61,518 | $1.14M |
| Squarepoint Ops LLC | 61,390 | $1.14M |
| Qube Research & Technologies Ltd | 33,187 | $614.0K |
| Maven Securities LTD | 27,486 | $508.0K |
| HRT Financial LP | 24,092 | $445.0K |
| Bank of Montreal | 23,000 | $414.0K |
| 683 Capital Management, LLC | 18,265 | $338.0K |
| Balyasny Asset Management LLC | 16,303 | $301.0K |
| Weiss Asset Management LP | 15,000 | $277.0K |
| Sciencast Management LP | 14,745 | $275.0K |
| Cannon Global Investment Management, LLC | 12,600 | $233.0K |
| Gyon Technologies Capital Management, LP | 12,187 | $225.0K |
| Dorsey Wright & Associates | 2,511 | $46.0K |
| Cutler Group LP | 1,550 | $28.0K |
| Ovata Capital Management Ltd | 400 | $7.00K |